Table 3.
Odds ratio | 95% CI | P-value | |
---|---|---|---|
Number of medications at the end | |||
0.1 (n = 372) | Reference | ||
2.3 (n = 261) | 0.34 | 0.22–0.51 | <0.001 |
4.5 (n = 153) | 0.13 | 0.08–0.23 | <0.001 |
≥6 (n = 98) | 0.18 | 0.10–0.34 | <0.001 |
Sex: Male | 2.20 | 1.18–4.08 | 0.013 |
Age (years) | |||
<40 (n = 144) | Reference | ||
40–49 (n = 387) | 0.74 | 0.44–1.23 | 0.245 |
50–59 (n = 301) | 0.39 | 0.23–0.68 | 0.001 |
≥60 (n = 52) | 0.37 | 0.15–0.89 | 0.026 |
Total number of consultations/3 yrs.(times) | |||
≥17 (n = 597) | Reference | ||
<17 (n = 287) | 27.1 | 15.6–47.0 | <0.001 |
DPP-4 inhibitor | 0.73 | 0.49–1.10 | 0.132 |
Biguanide | 0.62 | 0.40–0.96 | 0.512 |
Thiazolidine | 1.08 | 0.63–1.86 | 0.781 |
DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor.